Oxamniquine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Oxamniquine


'Oxamniquine' is "an anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia, 31st ed, p121)" more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

History

In 1979, Pfizer at Sandwich was presented with the Queen’s Award for Technological Achievement in recognition of the outstanding contribution made to tropical medicine by MANSIL™ (oxamniquine).

Pharmacokinetics

Peak plasma concentrations are achieved 1 to 3 hours after a dose and the plasma half-life is 1 to 2.5 hours.

It is extensively metabolised to inactive metabolites, principally the 6-carboxy derivative, which are excreted in the urine. About 70% of a dose of oxamniquine is excreted as the 6-carboxy metabolite within 12 hours of a dose; traces of the 2-carboxy metabolite have also been detected in the urine.

Mode of Action

Is a semisynthetic tetrahydroquinoline and possibly acts by DNA binding resulting in contraction and paralysis of the worms and eventual detachment from terminal venules in the mesentry and death.

Uses

For treatment of schistomiasis. According to one systematic review it is equally effective as praziquantel (for treating S. mansoni).

Contraindications and Precautions

Pregnancy

Side Effects

It is generally well tolerated following oral doses. Dizziness with or without drowsiness occurs in at least a third of patients, beginning up to 3 hours after a dose and usually lasting for up to 6 hours. Headache and gastrointestinal effects such as nausea, vomiting, and diarrhoea are also common.

Allergic-type reactions including urticaria, pruritic skin rashes, and fever may occur. Liver enzyme values have been raised transiently in some patients. Epileptiform convulsions have been reported, especially in patients with a history of convulsive disorders. Hallucinations and excitement have occurred rarely.

A reddish discoloration of urine, probably due to a metabolite of oxamniquine, has been reported.

Dosage

Oral, 15 mg per kg of body weight two times a day for one day.

Brandnames

  • Vansil; (Pfizer) 250 mg capsules, syrup 250 mg/5ml
  • Mansil; 250 mg Tablets

External References

  • AHFS Database

Read more at Wikipedia.org


[List your site here Free!]


Salmonella-S. mansoni association in patients with acquired immunodeficiency syndrome
From Revista do Instituto de Medicina Tropical de Sao Paulo, 7/1/98 by Lambertucci, J Roberto

SUMMARY

Two young men with Salmonella bacteraemia, active schistosomiasis and the acquired immunodeficiency syndrome are reported. The clinical presentation comprised nonspecific signs and symptoms, such as fatigue, malaise, weight loss, diarrhoea, prolonged fever, and hepatosplenomegaly. In one patient, liver biopsy showed poorly formed granulomata around Schistosoma mansoni eggs and hepatitis. Treatment of schistosomiasis alone induced consistent clinical improvement with eventual cure of both Salmonella and S. mansoni infections. Recognition of the Salmonella-S. mansoni association in patients with AIDS is important because treatment of schistosomiasis makes a difference, improving the prognosis of this otherwise, recurrent, potentially fatal bacteraemia.

KEYWORDS: Schistosomiasis; Salmonella; AIDS; Acquired immunodeficiency syndrome

J. Roberto LAMBERTUCCI, Abdunnabi A.M. RAYES & Rogerio GERSPACHER-LARA

INTRODUCTION

Salmonella bacteraemia occurs with increased frequency in infants, in the elderly and in patients with diseases associated with hemolysis (such as sickle cell diseases, malaria, and bartonellosis), with lymphoma, with leukemia, and with systemic lupus erythematosus4. Patients with AIDS develop recurrent, relapsing Salmonella bacteraemia that is difficult to cure with antibiotics'. In Subsaharan Africa gram-negative bacteraemia is second only to tuberculosis as a cause of death among HIV-infected individuals'. Chronic persistent Salmonella bacteraemia has also been described in association with S. mansoni infection. The most common characteristics of the clinical syndrome are': I) a long history of a febrile disease; II) bacteraemia with one of many species of the genus Salmonella; III) chronic active schistosomiasis. We report two patients with AIDS and Salmonella bacteraemia that have been cured of the Salmonella infection after treatment for schistosomiasis with oxamniquine.

CASE REPORTS

Patient 1: A 24-year-old, previously healthy white man, was hospitalized with fever, diarrhoea, and a 10-kg weight loss over three months. Physical examination showed an ill, pale, and wasted man with a temperature of 39.8 oC, with patchy alopecia, generalized lymphadenopathy and oral candidiasis. His abdomen was protuberant with hepatosplenomegaly and ascites. The right lobe of the liver was tender to palpation and extended 4 cm below the right costal margin. The spleen was palpable 6 cm below the left costal margin. Edematous infiltration of the skin, and pedal edema were also observed. Initial laboratory investigations showed pancytopenia (haemogloblin, 8.1 g/dl; white blood cells, 3000/cu mm; platelets, 65,000). His serum albumin was 1.7 g/dl; globulin, 4.5 g/dl. Three blood cultures grew Salmonella serogroup D. He tested HIV-positive by ELISA and western blot analysis. TCD4+ count was 265 cells/PI and TCD8+ was 1088 cells/pl. Serologic tests for cytomegalovirus, toxoplasmosis, hepatitis B and C, and a VDRL slide test were all negative. Liver biopsy specimens obtained during laparoscopy revealed poorly formed granulomata around S. mansoni eggs with scattered lymphocytes, plasma cells, and eosinophils; several areas of spotty necrosis of hepatocytes with lymphocyte and macrophage infiltration were documented.

The patient was easily irritable and agressive, and left the hospital prematurely, against medical advice. Just before dismissal, though, he was treated for schistosomiasis with oxamniquine (IS mg/kg, body weight, single dose). He did not accept the diagnosis of AIDS and refused treatment with antiretroviral drugs. Notwithstanding, during his occasional visits to the outpatient clinic a consistent clinical improvement was observed. The patient's fever and diarrhoea subsided 20 days after being discharged from the hospital. In the following two months his weight increased 15 kg. The ascites and oedema of the lower limbs vanished and he continued to improve for the next five months. There was an involution of the liver and spleen, the latter being just palpable. Three consecutive blood cultures remained sterile. His hemoglobin was 12.1 g/dl; white blood cells, 5600/cu mm, and platelets, 288,000. Serum albumin was 3.4 g/dl and globulin, 2.1 g/ dl. There was no significant increase in the lymphocyte subset counts on the occasion (TCD4+ = 273; TCD8+ = 1442). Cure of schistosomiasis was ascertained by 9 negative stool examinations for parasite ova performed along the 10 months of follow up after treatment. He was seen last time 18 months after the initial treatment for schistosomiasis and was asymptomatic.

Patient 2: A 26-year-old man with a history of homosexual activity was admitted with diarrhoea, fever, fatigue and weight loss of 11 kg over the last four months. For some time he rejected medical attention. Twenty days earlier, he was treated for schistosomiasis with oxamniquine in another hospital. He noticed significant clinical improvement after treatment but loose bowel movements and low fever persisted.

Axillary temperature on admission was 36.8 oC. His abdomen was flat but the right lobe of the liver and the spleen were easily palpable and painful to palpation. Salmonella enteritidis was recovered from three blood cultures and two stool cultures. In the fragments obtained by rectal biopsy viable eggs of S. mansoni were seen. The hemoglobin level was 10.8 g/dl. His serum albumin was 2.4 g/dl and globulin was 4.8 g/dl. His serum tested HIV-positive by ELISA and western blot analysis. TCD4+ count was 40 cells/pl and TCD8+ was 667 cells/pl. He remained afebrile during the time (15 days) that he stayed in our hospital.

He was seen at the outpatient clinic two months later and was asymptomatic. His spleen was not palpable and his weight increased 10 kg. Serum albumin was 4.3 g/dl and globulin 4.2 g/dl. TCD4+ count increased to 202 cells/pl and TCD8+ to 1317 cells/pl. Three parasitological stool examinations remained negative for S. mansoni ova 60 days after treatment; a rectal biopsy taken around the same time did not show viable eggs of the worm. Ten months after the first admission to hospital he is feeling well and have had no recurrences of the bacteraemia.

DISCUSSION

This is the first description of the Salmonella-S. mansoni association in patients with AIDS. Salmonella-S. mansoni association occurs most commonly in males between the ages of 10 and 30 years. The response to antibiotic therapy is dramatic s. However, recurrent Salmonella bacteraemia is common if the underlying schistosome disease is not treated.

It is interesting to note that patients with AIDS and Salmonella bacteraemia, without concurrent schistosomiasis, also show a very similar clinical picture to that presented by our patients, except for the good response to treatment with oxamniquine. Previous in vitro work has demonstrated that oxamniquine is not active against the bacteria'9. Hence, the most probable explanation for the clinical improvement of our patients after receiving oxamniquine is that treatment of schistosomiasis cured the S. mansoni infection and indirectly the Salmonella bacteraemia. Data on the behaviour of schistosomiasis mansoni in the immunosuppressed host are rather few2.

Depression of cell-mediated immune response in the host diminishes granulomatous response to S. mansoni eggs'. Mice experimentally infected with S. mansoni and immunosuppressed by drugs or thymectomy develop diffuse and severe hepatitis. Liver tissue of patient 1 showed diminished granulomatous response to Schistosoma mansoni eggs and areas of hepatocyte necrosis.

There is no clear explanation as to why Salmonella-S. mansoni association has not been seen by other investigators in patients with AIDS. The association may help to explain the high proportion of Salmonella bacteraemia reported in AIDS patients from Africa 35. It is probable that infection with S. mansoni may not even be considered by the physician examining a patient with AIDS and Salmonella bacteraemia.

In addition, the routine use of active drugs against Salmonella, in AIDS patients, like sulfametoxazol-trimethoprim or zidovudine may further distort the clinical features of this peculiar association 6.

It is also worth mentioning that egg output decreases sharply in mice experimentally infected with S. mansoni and immunosuppressed by drugs or thymectomy'. A well formed granuloma seems to facilitate the migration of eggs in the host tissues. Without granuloma formation, S. mansoni eggs do not reach (or only in small numbers) the gut lumen. Diagnosis of schistosomiasis, based on stool microscopy, in this context, should be reexamined. Rectal or liver biopsies, and ELISA tests for circulating antigens would represent an alternative to stool examination in such cases. Studies in patients with schistosomiasis and AIDS and low TCD4+ cell counts are mostly needed either to confirm or exclude this interesting hypothesis.

RESUMO

Associacao Salmonella-S. mansoni em pacientes com a sindrome da imunodeficiencia adquirida

Apresentam-se os casos de dois jovens com bacteriemia por Salmonella associada a esquistossomose mansoni ativa em pacientes com a sindrome da imunodeficiencia adquirida. A apresentaqao clinica incluiu sintomas e sinais inespecfficos como fadiga, perda de peso, diarreia, febre prolongada e hepatoesplenomegalia. A bi6psia hepatica em um paciente revelou granulomas mal formados em torno de ovos de S. mansoni e hepatite de intensidade moderada. O tratamento da esquistossomose com a oxamniquine induziu melhora clinica progressiva culminando com a cura da salmonelose e da esquistossomose. O reconhecimento da associacao Salmonella-S. mansoni em pacientes com AIDS mostra-se importante nesses casos pois o tratamento da esquistossomose melhora o progn6stico da bacteriemia por Salmonella que pode tornar-se reconente e fatal nos pacientes com AIDS.

ACKNOWLEDGMENTS

We thank Dr. Maria Cristina Fonseca for the serotyping of Salmonella and Dr. Nivaldo Hartung Toppa for the microscopy of liver fragments. This work was partially supported by CNPq-Brazil.

REFERENCES

1. DOENHOFF, M.J.; HASSOUNAH, O.; MURARE, H.; BAIN, J. & LUCAS, S. -The schistosome egg granuloma: immunopathology in the cause of host protection or parasite survival? Trans. roy. Soc. trop. Med. Hyg., 80: 503514, 1986.

2. DOENHOFF, M.J.; MODHA, J.; LAMBERTUCCI, J.R. & MCLAREN, D. J. - The immune dependence of chemotherapy. Parasit. today, 7: 16-18, 1991. 3. GILKS, C.F.; OTIENO, L.S.; BRINDLE, R.J. et al. - The presentation and outcome of HIV-related disease in Nairobi. Quart. J. Med., 82: 25-32,1992. 4. JONES, B.D. & FALKO, W.S. - Salmonellosis: host immune responses and bacterial determinants. Ann. Rev. Immunol., 14: 533-561,1996. 5. KAPLAN, J.E.; DALE, J.; HOLMES, K.K. et al. - Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the world. Amer. J. trop. Med. Hyg., SS: 1-11, 1996. 6. KEITH, B.R.; WHITE, G. & WILSON, H.R. - In vivo efficacy of zidovudine in experimental gram-negative bacterial infections. Antimicrob. Agents Chemother., 33: 479-483, 1989.

7. LAMBERTUCCI, J. R. - S. mansoni: pathological and clinical aspects. In: JORDAN, P.; WEBBE, G.; STURROCK, R.F., ed. Human schistosomiasis. Wallingford, CAB International, 1993. p. 320-360. 8. LAMBERTUCCI, J.R.; GODOY, P.; BAMg IRRA, E.A. & FERREIRA, M. D. - Glomerulonephritis in Salmonella-S. mansoni association. Amer. J. trop. Med. Hyg., 38: 97-102, 1988.

9. LAMBERTUCCI, J.R.; MARINHO, R.P.; FERREIRA, M.D.; NEVES, J. & PEDROSO, E.R.P. - Therapeutic efficacy of oxamniquine in the treatment of Salmonella-S. mansoni association. Rev. Inst. Med. trop. S. Paulo, 27: 33-39, 1985.

10. LEVINE, W.C.; BUEHLER, J.W.; BEAN, N.C. & TAUXE, R.V. - Epidemiology of non-typhoidal Salmonella bacteremia during the human immunodeficiency virus epidemic. J. infect. Dis., 164: 81-87, 1991. II. NEVES, J. & MARTINS, N.R.L.L. - Long duration of septicaemic salmonellosis: 35 cases with 12 implicated species of Salmonella. Trans. roy. Soc. trop. Med. Hyg., 61: 541-552, 1967.

( I ) Departamento de Clinica Mddica, Faculdade de Medicina da UFMG, Belo Horizonte, MG, Brasil. Correspondence to: Dr. J. R. Lambertucci, Departamento de Clinica Mddica, Faculdade de Medicina da UFMG. Av. Alfredo Balena 190. 30130-100 Belo Horizonte, MG, Brasil. E-mail: lamber@net.em.com.br

Copyright Instituto de Medicina Tropical de Sao Paulo Jul/Aug 1998
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Oxamniquine
Home Contact Resources Exchange Links ebay